{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:04:16Z","timestamp":1785279856688,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Modifications in the gut microbiota may be a crucial factor in the efficacy of canagliflozin (Cana) in managing patients with type 2 diabetes mellitus (T2DM). However, the interplay between oral and ocular surface microbiota and this treatment remains poorly explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This study aimed to assess alterations in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment in patients with T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this 30-day, controlled before-and-after study, 21 treatment-na\u00efve patients with T2DM received sole treatment with Cana (100 mg\/day), and were matched with 10 healthy controls based on gender and age. Using 16S rRNA sequencing, changes in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment were assessed and compared with those of healthy controls. Concurrently, diabetes-related clinical parameters were recorded over the study period. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR200034878).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A noticeable shift was observed in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment. The post-Cana treatment gut microbiota was more similar to that of the healthy controls. Network correlation analysis revealed that modifications in the gut, oral, and ocular surface microbiota were related to changes in clinical parameters, especially for the ocular surface microbiota.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical parameters<\/jats:title><jats:p>A significant decrease in fasting plasma glucose (8.22 \u00b1 2.19 <jats:italic>vs<\/jats:italic> 6.87 \u00b1 1.09 mmol\/L), glycated serum protein [291.00 (264.00, 353.00) <jats:italic>vs<\/jats:italic> 275.00 (251.00, 342.50) \u03bcmol\/L], hemoglobin A1c (7.39 \u00b1 1.18 <jats:italic>vs<\/jats:italic> 7.12 \u00b1 1.33%), body mass index (25.32 \u00b1 2.99 <jats:italic>vs<\/jats:italic> 24.83 \u00b1 2.95 kg\/m<jats:sup>2<\/jats:sup>), systolic blood pressure (129.05 \u00b1 17.51 <jats:italic>vs<\/jats:italic> 123.43 \u00b1 14.82 mmHg), and urinary creatinine [158.40 (74.75, 219.15) <jats:italic>vs<\/jats:italic> 79.70 (56.25, 138.10) \u03bcmmol\/kg] levels was noted after 30-day Cana monotherapy (<jats:italic>P<\/jats:italic> &amp;lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Gut microbiome<\/jats:title><jats:p>Treatment with Cana resulted in an increase in the relative abundance of short-chain fatty acid (SCFA)-producing bacteria, particularly <jats:italic>Lachnospiraceae UCG 004<\/jats:italic>, <jats:italic>Bacteroides<\/jats:italic>, and <jats:italic>Lachnospiraceae NK4A136 group<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Oral microbiota<\/jats:title><jats:p>After Cana treatment, a significant increase of <jats:italic>Prevotella<\/jats:italic> and <jats:italic>Veillonella<\/jats:italic>, both of which are known to be closely associated with SCFAs, was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ocular surface microbiota<\/jats:title><jats:p>Post-Cana administration, the ocular surface microbiota exhibited the most distinct changes in structure and composition. Remarkably, the majority of the increased ocular surface microbiota could produce SCFAs within the gut microbiota.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cana effectively improved the dysregulated glucose metabolism in patients with T2DM. This improvement can potentially be attributed to the restoration of balance among the gut, oral, and ocular surface microbial communities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/www.chictr.org.cn\/showproj.html?proj=56487<\/jats:uri>, identifier ChiCTR2000034878.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1256292","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:10:57Z","timestamp":1696518657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus"],"prefix":"10.3389","volume":"14","author":[{"given":"Limin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiudan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/s2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.691878","article-title":"Canagliflozin for prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Tian","year":"2021","journal-title":"Front Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","article-title":"Role of gut microbiota in type 2 diabetes pathophysiology","volume":"51","author":"Gurung","year":"2020","journal-title":"EBioMedicine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.06.004","article-title":"Arrhythmic gut microbiome signatures predict risk of type 2 diabetes","volume":"28","author":"Reitmeier","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40168-020-00821-0","article-title":"Gut microbiota and cardiovascular disease: opportunities and challenges","volume":"8","author":"Kazemian","year":"2020","journal-title":"Microbiome"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.839640","article-title":"Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and gut microbiota dysbiosis in mice with diabetic cardiovascular disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac210","article-title":"Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes","volume":"107","author":"Deng","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature11234","article-title":"Structure, function and diversity of the healthy human microbiome","volume":"486","year":"2012","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4526","article-title":"Ectopic colonization of oral bacteria in the intestine drives T(H)1 cell induction and inflammation","volume":"358","author":"Atarashi","year":"2017","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.06.014","article-title":"Diabetes enhances IL-17 expression and alters the oral microbiome to increase its pathogenicity","volume":"22","author":"Xiao","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1038\/s41598-022-08442-3","article-title":"Gut-derived butyrate suppresses ocular surface inflammation","volume":"12","author":"Schaefer","year":"2022","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-022-01243-w","article-title":"Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain","volume":"10","author":"Parker","year":"2022","journal-title":"Microbiome"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00202","article-title":"How ocular surface microbiota debuts in type 2 diabetes mellitus","volume":"9","author":"Li","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000713","article-title":"Characterization of the oral fungal microbiome (mycobiome) in healthy individuals","volume":"6","author":"Ghannoum","year":"2010","journal-title":"PloS Pathog"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1219","article-title":"The SILVA ribosomal RNA gene database project: improved data processing and web-based tools","volume":"41","author":"Quast","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/srep09053","article-title":"A Filifactor alocis-centered co-occurrence group associates with periodontitis across different oral habitats","volume":"5","author":"Chen","year":"2015","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.63.13.20","article-title":"Microbiological characteristics of ocular surface associated with dry eye in children and adolescents with diabetes mellitus","volume":"63","author":"Chen","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.32584","article-title":"Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan","volume":"5","author":"Su","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1017\/s095442241700018x","article-title":"Probiotics, prebiotics, synbiotics and insulin sensitivity","volume":"31","author":"Kim","year":"2018","journal-title":"Nutr Res Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105420","article-title":"The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis","volume":"165","author":"Liu","year":"2021","journal-title":"Pharmacol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature12726","article-title":"Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation","volume":"504","author":"Arpaia","year":"2013","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2022.114175","article-title":"Arsenolipids reduce butyrate levels and influence human gut microbiota in a donor-dependent way","volume":"246","author":"Calatayud","year":"2022","journal-title":"Ecotoxicol Environ Saf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jaci.2021.03.028","article-title":"Multidimensional study of the oral microbiome, metabolite, and immunologic environment in peanut allergy","volume":"148","author":"Ho","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1053\/j.gastro.2018.04.028","article-title":"Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer","volume":"155","author":"Kwong","year":"2018","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41588-021-00968-y","article-title":"Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome","volume":"54","author":"Liu","year":"2022","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2013.06.003","article-title":"Faecalibacterium prausnitzii and human intestinal health","volume":"16","author":"Miquel","year":"2013","journal-title":"Curr Opin Microbiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1256292\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T15:11:01Z","timestamp":1696518661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1256292\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":29,"alternative-id":["10.3389\/fendo.2023.1256292"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1256292","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"article-number":"1256292"}}